Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor OPtimization and Selectivity trial

Haematologica

Volumn 97, Issue 5, 2012, Pages 731-738

  Guilhot, François ^a   Hughes, Timothy P ^b   Cortes, Jorge ^c   Druker, Brian J ^d   Baccarani, Michele ^e   Gathmann, Insa ^f   Hayes, Michael ^f   Granvil, Camille ^f   Wang, Yanfeng ^f  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic myeloid leukemia; Imatinib; Pharmacokinetics; Tyrosine kinase inhibitor

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL) BENZAMIDO] ANILINO] 4 (3 PYRIDYL) PYRIMIDINE; IMATINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD LEVEL; BODY SURFACE; BODY WEIGHT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; EYELID EDEMA; FACE EDEMA; FATIGUE; FEMALE; GENDER; HEADACHE; HUMAN; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; RANDOMIZED CONTROLLED TRIAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TROUGH PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860549849     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.045666     Document Type: Article

References (44)

1. National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology. Chronic Myelogenous Leukemia. Version 2. 2011.
2. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-6051.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic- phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
5. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114(22):462 [abstract 1126].
6. Larson RA, Druker BJ, Guilhot FA, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022-4028.
7. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496-3499.
8. Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010;55(11):731-737.
9. Takahashi N, Wakita H, Miura M, Scott SA, Nishii K, Masuko M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther. 2010;88(6):809-813.
10. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003;102(1):83-86.
11. Kantarjian H, Talpaz M, O'Brien S, Garcia- Manero G, Verstovsek S, Giles F, et al. Highdose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103(8):2873-2878.
12. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112(10):3965-3973.
13. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, et al. Highdose imatinib in newly diagnosed chronicphase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27(28):4754-4759.
14. Rea D, Etienne G, Corm S, Cony-Makhoul P, Gardembas M, Legros L, et al. Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. Leukemia. 2009;23 (6):1193-1196.
15. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009;115(3):551-60.
16. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard- dose imatinib therapy. Blood. 2009; 113(10):2154-2160.
17. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3):424-430.
18. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCRABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
19. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925-1930.
20. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.
21. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography- tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;768(2):325-340.
22. Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol. 2005;60(1):35-44.
23. Larson RA, Chia YL, Granvil C, Guilhot F, Druker BJ, O'Brien SG, et al. Steady-state imatinib trough levels as well as dose interruptions are associated with clinical response (CCyR and MMR) and adverse events (AEs) in patients with chronic myeloid leukemia (CML) receiving IM as frontline therapy. Blood. 2009;114(22):872 [abstract 2213].
24. Baccarani M, Druker BJ, Cortes-Franco J, Hughes TP, Kim DW, Pane F, et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood. 2009;114(22):142 [abstract 337].
25. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652-61.
26. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
27. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388.
28. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.
29. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25(6): 481-496.
30. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
31. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004;26(2):192-9.
32. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance Blood. 2004;104(12):3739-3745.
33. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008;83 (2):258-264.
34. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT- 1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108(2):697-704.
35. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28(16):2761-2767.
36. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 2008;14(10):3141-3148.
37. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib Blood. 2005;106 (3):1133-1134.
38. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 2007; 82(1):33-40.
39. Illmer T, Schaich M, Platzbecker U, Freiberg- Richter J, Oelschlagel U, von Bonin M, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18(3):401-408.
40. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110(12):4064-4072.
41. Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D. OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma. 2008;49(11): 2222-2223.
42. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31(5): 579-584.
43. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362 (24):2251-2259.
44. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.